| Market Cap | ₹209.96 CrSmall Cap |
|---|---|
| P/E Ratio | 41.43Sector PE 45.87 |
| RSI | 52.19Neutral Zone |
| Promoter Holding | 73.48%No pledge |
| Metric | H1-27 | H2-26 | H1-26 |
|---|---|---|---|
| Revenue from Operations | 29.4 | 19.5 | 14.1 |
| Other Income | 0.2 | 0.1 | 0.0 |
| Total Income | 29.6 | 19.6 | 14.1 |
| Profit Before Tax | 5.7 | 3.3 | 2.9 |
| Net Profit | 4.7 | 2.7 | 2.4 |
| Operating Margin | 19.3% | 16.8% | 20.6% |
| Net Profit QoQ | +74.1% | ||
| Net Profit YoY | +95.8% | ||
| Adj. Profit QoQ | +71.9% | ||
| Adj. Profit YoY | +89.7% | ||
Key highlights
- Net profit reached ₹4.7 crore in H1-27, up from ₹2.4 crore in H1-26
- Revenue from operations grew to ₹29.4 crore compared to ₹14.1 crore in the year-ago period
- Operating margins stood at 19.3% for the half-year ended September 2026
- Profit before tax increased to ₹5.7 crore, a 96.5% rise over the ₹2.9 crore reported in H1-26
- The company fully utilized its IPO proceeds of ₹24.77 crore as of September 30, 2026
Expansion in Nutraceutical Wellness Markets
Accretion Nutraveda has demonstrated sharp operational scaling in the pharmaceutical and biotechnology sector, with H1-27 revenue climbing to ₹29.4 crore from ₹14.1 crore in H1-26. This 108.5% revenue growth follows the company's listing on the BSE SME platform on February 4, 2026. The firm maintains its focus on the manufacture and trade of nutraceutical wellness products, which it considers its primary business segment.
Other income also saw a marginal increase to ₹0.2 crore, contributing to a total income of ₹29.6 crore for the six-month period ending September 2026.
Full Deployment of IPO Capital
- ₹4.22 crore utilized for purchase of machineries for automation in existing units
- ₹8.03 crore deployed for new manufacturing setup equipment
- ₹5.50 crore allocated to funding working capital requirements
- ₹3.69 crore utilized for general corporate purposes as per the prospectus
- ₹3.33 crore accounted for IPO-related expenses, completing the fund utilization
Strategic Financial Structuring
The company's profitability has nearly doubled year-on-year, with net profit reaching ₹4.7 crore. This represents a 74.1% sequential growth over the H2-26 profit of ₹2.7 crore. Beyond operational gains, the company is positioning for further expansion, having secured shareholder approval on October 9, 2026, to increase its borrowing limit to ₹500 crore.
Current market data shows a Price-to-Earnings ratio of 41.43, trading slightly below the industry average of 40.83 and the broader sector PE of 45.87, reflecting a steady valuation despite the rapid growth in bottom-line figures.
| Date | Announcement | Amount |
|---|---|---|
| 08 May 2026 | Audited H2 FY26 Net ProfitSource: livemint.com | ₹2.74 Cr |
| 08 May 2026 | Audited H2 FY26 Revenue from OperationsSource: tradebrains.in | ₹19.54 Cr |
| 08 May 2026 | Audited FY26 Net ProfitSource: scanx.trade | ₹5.07 Cr |
| 08 May 2026 | Audited FY26 Revenue from OperationsSource: BSE filing | ₹33.60 Cr |
| 21 Jan 2026 | Restated H1 FY26 Net ProfitSource: m.economictimes.com | ₹2.33 Cr |
| 21 Jan 2026 | Restated H1 FY26 Revenue from OperationsSource: ipoplatform.com | ₹14.06 Cr |
What to watch next
- Execution of expansion projects following the approval of the ₹500 crore borrowing limit on October 9, 2026
- Operational efficiency gains from newly installed automated machinery in existing manufacturing units
- Next financial results announcement scheduled for early 2027
| Share price | ₹290 |
|---|---|
| Market capitalisation | ₹209.96 Cr |
| Revenue (annual) | ₹33.60 Cr |
| Net profit (annual) | ₹5.07 Cr |
| P/E (TTM) | 41.43×Sector 45.87× |
| Promoter holding | 73.48%0.00% QoQ |
| FII holding | 1.08%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Accretion Nutraveda Ltd announcing unaudited financial results for the half-year ended September 30, 2026. Market figures from a third-party data provider.
